Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment

被引：26

作者：

Menichelli, Danilo ^{[1
]}

Vicario, Tommasa ^{[2
,3
]}

Ameri, Pietro ^{[4
,6
]}

Toma, Matteo ^{[4
,6
]}

Violi, Francesco ^{[1
,5
]}

Pignatelli, Pasquale ^{[1
,5
]}

Pastori, Daniele ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy

[2] Sapienza Univ Rome, Dept Gen Surg & Surg Specialties Paride Stefanini, Rome, Italy

[3] Policlin Tor Vergata Hosp, Emergency Dept, Rome, Italy

[4] IRCCS Osped Policlin San Martino, Cardiovasc Dis Unit, Genoa, Italy

[5] Mediterranea Cardioctr, Naples, Italy

[6] Univ Genoa, Dept Internal Med, Genoa, Italy

来源：

PROGRESS IN CARDIOVASCULAR DISEASES | 2021年 / 66卷

关键词：

Atrial fibrillation; Cancer; Oral anticoagulants; Chemotherapy; Radiotherapy; DOACs; DIRECT ORAL ANTICOAGULANTS; OXIDATIVE STRESS; RISK-FACTORS; CARDIOVASCULAR TOXICITY; POSITION PAPER; 2016; ESC; WARFARIN; SAFETY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

D O I：

10.1016/j.pcad.2021.04.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cancer patients are at an increased risk of developing atrial fibrillation (AF) and thrombosis. However, the management of anticoagulation in patients with both diseases may be challenging, and data on these patients are lacking. We summarize the current evidence on the incidence and prevalence of cancer in AF and vice versa and provide some practical considerations on the management of oral anticoagulation in specific clinical situations. Low-molecular weight heparins are not approved for thromboprophylaxis in AF, and management of warfarin can be difficult. The use of direct oral anticoagulants may be particularly attractive for their rapid onset/ offset action and lower bleeding risk. (c) 2021 Elsevier Inc. All rights reserved.

引用

页码：28 / 36

页数：9

共 50 条

[1] Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation
Ferreira Lisboa Da Silva, Rose Mary
Miranda, Claudia Madeira
Liu, Tong
Tse, Gary
Roever, Leonardo
FRONTIERS IN NEUROSCIENCE, 2019, 13
[2] Atrial Fibrillation and Cancer-Epidemiology, Mechanisms, and Management
Davis, Nathaniel E.
Prasitlumkum, Narut
Tan, Nicholas Y.
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (24)
[3] Epidemiology and mechanisms of atrial fibrillation
Lacroix, D.
Klein, C.
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2020, 204 (08): : 846 - 853
[4] Atrial fibrillation: Epidemiology, mechanisms, and management
Sra, J
Dhala, A
Blanck, Z
Deshpande, S
Cooley, R
Akhtar, M
CURRENT PROBLEMS IN CARDIOLOGY, 2000, 25 (07) : 413 - 524
[5] Anticoagulation for atrial fibrillation in active cancer
Farmakis, Dimitrios
Papakotoulas, Pavlos
Angelopoulou, Eleni
Bischiniotis, Theodoros
Giannakoulas, George
Kliridis, Panagiotis
Richter, Dimitrios
Paraskevaidis, Ioannis
ONCOLOGY LETTERS, 2022, 23 (04)
[6] Anticoagulation for Atrial Fibrillation in Patients With Cancer
Yasui, Taku
Fujita, Masashi
CIRCULATION JOURNAL, 2022, 86 (02) : 211 - 212
[7] Anticoagulation for atrial fibrillation: Epidemiology informing a difficult clinical decision
Singer, DE
PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1996, 108 (01) : 29 - 36
[8] Atrial fibrillation: Epidemiology, mechanisms, and management - Foreword
O'Rourke, RA
CURRENT PROBLEMS IN CARDIOLOGY, 2000, 25 (07) : 409 - 409
[9] Management of Anticoagulation in Cancer Patients with Atrial Fibrillation
Szmit, Sebastian
Kepski, Jaroslaw
Wilk, Michal
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2022, 24 (03): : 183 - 185
[10] Anticoagulation for atrial fibrillation in patients with active cancer
Sorigue, M.
Sarrate, E.
Miljkovic, M. D.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 280 : 98 - 98

← 1 2 3 4 5 →